Tjho-Heslinga R E, Kakebeeke-Kemme H M, Davelaar J, de Vroome H, Bleeker J C, Oosterhuis J A, Leer J W
Department of Clinical Oncology, Academic Hospital, Leiden, Netherlands.
Radiother Oncol. 1993 Oct;29(1):33-8. doi: 10.1016/0167-8140(93)90170-d.
The follow-up results are presented for the radiotherapeutic treatment of 49 patients with uveal eye melanoma using ruthenium-106 (106Ru/106Rh) applicators. Graded doses were applied and the degree of regression was found to be correlated with the dose at the top of the tumour. Complete regression is found in 66% of the patients treated with a top dose above 150 Gy, in which case the initial tumour prominence diminishes in about three years to a stable disease or to a flat scar. At this dose a marginal increase in complications was observed as compared with lower dose groups. Useful vision could be preserved in 75% of the eyes.
